Skip to content

Study · Non-randomized trial · n = 57 · 2012

3 results

Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.

Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M and 11 more

Show all authors

Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T

Spine1 Nov 2012Cited by 149 (Europe PMC)

PMID22872218 (opens in a new tab)DOI10.1097/brs.0b013e31826ca2a8 (opens in a new tab)PepBankPUB-22872218
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis undergoing lumbar fusion, postoperative pain scores did not differ significantly between teriparatide and risedronate groups.

    In plain wordsIn women with osteoporosis after spinal fusion, pain scores did not differ significantly between teriparatide and risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePostoperative pain score
    Study

    n = 57

    Comparator
    Risedronate
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pain scores improved after surgery; however, no significant difference was noted between the groups after surgery.
    2 context sentences
    Summary · context
    Fifty-seven women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 2 treatment groups, a teriparatide group (n = 29; daily subcutaneous injection of 20 μg of teriparatide) and a bisphosphonate group (n = 28; weekly oral administration of 17.5 mg of risedronate).
    Summary · context
    All patients underwent decompression and 1- or 2-level instrumented posterolateral fusion with a local bone graft.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis undergoing lumbar fusion, bone union was significantly more frequent with teriparatide than with risedronate.

    In plain wordsIn women with osteoporosis after spinal fusion, bone union occurred more often with teriparatide than with risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone union rate
    Study

    n = 57

    Comparator
    Risedronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneousAs given in this study (human).

    Measurements

    Bone union rate
    82%
    teriparatide
    Bone union rate
    68%
    bisphosphonate

    Source sentences

    Summary
    The rate of bone union was 82% in the teriparatide group and 68% in the bisphosphonate group.
    3 context sentences
    Summary · context
    The rate of bone union and average of duration of bone union in the teriparatide group patients were significantly superior to those in the bisphosphonate group.
    Summary · context
    Fifty-seven women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 2 treatment groups, a teriparatide group (n = 29; daily subcutaneous injection of 20 μg of teriparatide) and a bisphosphonate group (n = 28; weekly oral administration of 17.5 mg of risedronate).
    Summary · context
    All patients underwent decompression and 1- or 2-level instrumented posterolateral fusion with a local bone graft.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis undergoing lumbar fusion, average time to bone union was significantly shorter with teriparatide than with risedronate.

    In plain wordsIn women with osteoporosis after spinal fusion, bone union took less time with teriparatide than with risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseDuration to bone union
    Study

    n = 57

    Comparator
    Risedronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneousAs given in this study (human).

    Measurements

    Average time to bone union
    8 months
    teriparatide
    Average time to bone union
    10 months
    bisphosphonate

    Source sentences

    Summary
    Average duration of bone union was 8 months in the teriparatide group and 10 months in the bisphosphonate group. The rate of bone union and average of duration of bone union in the teriparatide group patients were significantly superior to those in the bisphosphonate group.
    2 context sentences
    Summary · context
    Fifty-seven women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 2 treatment groups, a teriparatide group (n = 29; daily subcutaneous injection of 20 μg of teriparatide) and a bisphosphonate group (n = 28; weekly oral administration of 17.5 mg of risedronate).
    Summary · context
    All patients underwent decompression and 1- or 2-level instrumented posterolateral fusion with a local bone graft.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.